Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NHS

NICE recommends two more cancer drugs for routine NHS use

The National Institute for Health and Care Excellence (NICE), the health technology assessment body, has issued positive opinions on two bowel cancer drugs, cetuximab and panitumumab, that were previously available through the cancer drugs fund (CDF). 

The decision means that the NHS must make funding available for both treatments for routine use within three months, once the final guidance is published. 

Under the guidance, both drugs can be used first-line in combination with FOLFOX or FOLFIRI chemotherapy for patients with wild-type RAS metastatic colorectal cancer. The decision expands the indication for cetuximab under NICE’s technology appraisal, which previously extended only to liver metastases specifically. Panitumumab has not previously been appraised by NICE. 

The drugs will be available through a patient access scheme at an undisclosed discount to the NHS. 

NICE also says that these approvals mark the halfway point in the CDF reappraisal process, which began when the revamped version of the CDF was launched in July 2016. NICE can now either recommend cancer drugs for routine commissioning on the NHS, recommend them for CDF use, or not recommend them at all. It is reappraising 24 drugs across 33 indications and so far 14 drugs for 18 indications have been moved from the old CDF into routine NHS use. 

andrew-dillon-chief-executive-national-institute-for-health-and-care-excellence-NICE

Source: Courtesy: NICE

NICE chief executive Sir Andrew Dillon says the good news for patients is that more cancer drugs than ever are being recommended for routine use

NICE says that the reappraisal process has led to pharmaceutical companies reviewing and reducing their drug prices, as well as several providing additional evidence. 

“The system is working well,” says NICE chief executive Sir Andrew Dillon. “Companies are cooperating well with our reviews and the good news for patients is that more cancer drugs than ever are being recommended for routine use.” 

Cetuximab, which is marketed as Erbitux by Merck, was deemed not cost-effective for use in squamous cell head and neck cancer by NICE in November 2016. Panitumumab is marketed as Vectibix by Amgen.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202409

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £37.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £42.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £37.00Buy now
  • Non-prescription Medicines

    Non-prescription Medicines

    Reviews over-the-counter medicines, arranged by the conditions they are licensed to treat. Includes product recommendations.

    £37.00Buy now
  • FASTtrack: Pharmaceutics - Drug Delivery and Targeting

    FASTtrack: Pharmaceutics - Drug Delivery and Targeting

    Pharmaceutics: Drug Delivery and Targeting systematically reviews important concepts for drug delivery systems and targeting of drugs.

    £24.00Buy now
  • Martindale: The Complete Drug Reference

    Martindale: The Complete Drug Reference

    Martindale: The Complete Drug Reference provides reliable, unbiased and evaluated information on drugs and medicines used throughout the world.

    £550.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • andrew-dillon-chief-executive-national-institute-for-health-and-care-excellence-NICE

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.